Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 225 participants.
Also called NCT02891850
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 225 participants
- Sponsor
- Registry
-
NCT02891850 -
2016-001067-36
-
- Other papers using this trial's data
- Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Austria, Belgium, Brazil, Canada, Czechia, Denmark, France, Germany, Greece, Italy, Japan, Mexico, Netherlands, Poland, Portugal, South Korea, Spain, Taiwan, Türkiye, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02891850. Randomized; no masking; primary purpose treatment. Start 2017-01-11 (actual); primary completion 2020-01-29 (actual). Results posted on 2021-01-22.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy
- Acronym
- REPLACE
- Condition
- Pulmonary Arterial Hypertension
- Intervention (Drug)
- Riociguat (Adempas, BAY63-2521)
- Intervention (Drug)
- Sildenafil
- Intervention (Drug)
- Tadalafil
- Lead sponsor
- Bayer
Record details
- Record id
cardio:ct-nct02891850- Content hash
34be75d09e1890137e21ab9cb2f0c69da097f13ce335ebbb3946d48b7ea80fbf